Foghorn Therapeutics (FHTX) Revenue & Revenue Breakdown
Foghorn Therapeutics Revenue Highlights
Latest Revenue (Y)
$22.60M
Latest Revenue (Q)
$7.56M
Foghorn Therapeutics Revenue by Period
Foghorn Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $22.60M | -33.83% |
| 2023-12-31 | $34.16M | 77.63% |
| 2022-12-31 | $19.23M | 1357.77% |
| 2021-12-31 | $1.32M | 206.74% |
| 2020-12-31 | $430.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Foghorn Therapeutics generated $22.60M in revenue during NA 2024, up -33.83% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Foghorn Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $7.56M | 26.97% |
| 2025-03-31 | $5.95M | 108.40% |
| 2024-12-31 | $2.86M | -63.42% |
| 2024-09-30 | $7.81M | 13.36% |
| 2024-06-30 | $6.89M | 36.40% |
| 2024-03-31 | $5.05M | -12.46% |
| 2023-12-31 | $5.77M | -66.99% |
| 2023-09-30 | $17.48M | 212.16% |
| 2023-06-30 | $5.60M | 5.46% |
| 2023-03-31 | $5.31M | 26.89% |
| 2022-12-31 | $4.18M | -36.93% |
| 2022-09-30 | $6.63M | 47.75% |
| 2022-06-30 | $4.49M | 14.54% |
| 2022-03-31 | $3.92M | 449.79% |
| 2021-12-31 | $713.00K | 1639.02% |
| 2021-09-30 | $41.00K | -85.30% |
| 2021-06-30 | $279.00K | -2.45% |
| 2021-03-31 | $286.00K | 13.94% |
| 2020-12-31 | $251.00K | 40.22% |
| 2020-09-30 | $179.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Foghorn Therapeutics generated $7.56M in revenue during Q2 2025, up 26.97% compared to the previous quarter, and up 149.64% compared to the same period a year ago.
Foghorn Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRDA | Entrada Therapeutics | $210.78M | $20.56M |
| ENTA | Enanta Pharmaceuticals | $67.64M | $18.31M |
| SLN | Silence Therapeutics | $43.26M | $142.00K |
| FHTX | Foghorn Therapeutics | $22.60M | $7.56M |
| IVA | Inventiva | $17.48M | $2.73M |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| IMRX | Immuneering | - | - |
| VTYX | Ventyx Biosciences | - | - |
| ZURA | Zura Bio | - | - |
| SGMT | Sagimet Biosciences | - | - |
| AVIR | Atea Pharmaceuticals | - | - |